For example, GBM patients are often treated with temozolomide, however the expression of the enzyme O6-Methylguanin-DNA-Methyltransferase MGMT, which removes DNA adducts caused by the DNA alkylating drug temozolomide, makes the drug inefficient in the GBM patient population expressing MGMT. This evidence concerns the gene MGMT and glioblastoma.